TMCnet News
Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia & Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market - Research and MarketsResearch and Markets has announced the addition of the "Global Respiratory Complications Therapeutics Market to 2022 - Innovative Pneumonia and Pulmonary Arterial Hypertension Therapies Dominate Varied Disease Market" report to their offering. Respiratory complications are a diverse set of indications that include respiratory disorders, cardiovascular disorders and infectious diseases. They are therefore associated with a broad range of underlying pathophysiology, which is reflected in the range of therapies in development in the pipeline. Overall, there are 843 products in active development in the respiratory complications pipeline. However, this constitutes numerous individual indications, each of which is typically relatively small in terms of the number of pipeline products in development. The most prominent individual indications in terms of respiratory complications therapeutics development are Pneumonia, Tuberculosis (TB), Respiratory Syncytial Virus (RSV) and Pulmonary Arterial Hypertension (PAH), which reflects the active nature of these indications n terms of overall product development. The respiratory complications market is forecast to grow moderately over the forecast period, from a value of $21.8 Billion in 2015 to $30.2 Billion in 2022, at a compound annual growth rate (CAGR) of 4.7%. This growth will be predominantly driven by already marketed products, rather than the approval of pipeline products, which are expected to have a limited impact on the market. Furthermore, generic impact on the market will be limited in terms of value, given the very low cost of generics typically used. There are few drugs that generate substantial revenue in the current respiratory complications market, with only one generating over $1 Billion from revenues specific to these complications. This is the Prevnar family pneumococcal disease vaccine, which has been approved for a broad spectrum of patients, ranging from six-week-old infants to adults of 50 and over. In 2015 the vaccine family generated $6.3 Billion, and this level of revenue is expected to remain relatively stable over the forecast period. Pfizer is expected to maintain its position as market leader throughout the entire forecast period. Companies Mentioned
Key Topics Covered: 1 Introduction 2 Therapy Area Introduction 3 Marketed Products 4 Pipeline Landscape Assessment 5 Multi-scenario Market Forecast to 2022 6 Company Analysis and Positioning 7 Strategic Consolidations 8 Appendix For more information about this report visit http://www.researchandmarkets.com/research/bc875t/global View source version on businesswire.com: http://www.businesswire.com/news/home/20170406005616/en/ |
